How is a CJC-1295 and ipamorelin vial dosed and mixed?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Filled in from the blend in the Milligram app's catalogue (5 mg + 5 mg). Change them to match your vial.
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds CJC-1295 + Ipamorelin and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
Of the people logging the blend in Milligram, 19% set up a 200 mcg dose, the most logged dose, though no label gives a dose for the blend, a DailyMed search returned no label for CJC-1295 or ipamorelin, and the human trials tested CJC-1295 with DAC under the skin and ipamorelin by intravenous infusion.101234
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 10 mg76% set up10 | 10 mg/mL: 200 mcg is 2 units, 300 mcg is 3 units, 500 mcg is 5 units | 5 mg/mL: 200 mcg is 4 units, 300 mcg is 6 units, 500 mcg is 10 units | 3.333 mg/mL: 200 mcg is 6 units, 300 mcg is 9 units, 500 mcg is 15 units |
| 20 mg16% set up10 | 20 mg/mL: 200 mcg is 1 unit, 300 mcg is 1.5 units, 500 mcg is 2.5 units | 10 mg/mL: 200 mcg is 2 units, 300 mcg is 3 units, 500 mcg is 5 units | 6.667 mg/mL: 200 mcg is 3 units, 300 mcg is 4.5 units, 500 mcg is 7.5 units |
Most often logged by Milligram users: 200 mcg, 19% logged.10
The 10 mg vial and how it is mixed
A DailyMed search returned no label for CJC-1295 or ipamorelin, and a vendor page lists the blend as a lyophilised 10 mg vial holding 5 mg of CJC-1295 (no DAC) and 5 mg of ipamorelin.125 Of the people logging it, 76% set up a 10 mg vial and 16% a 20 mg vial.10 The mix most often logged is 10 mg with 2 mL (43%).10 Others logged were 10 mg with 1 mL (11%) and 20 mg with 3 mL (10%).10 No label gives a mixing water or volume for either peptide; the only label with mixing steps found is for tesamorelin, a different compound (tesamorelin dosage), which uses 0.5 mL of its supplied Sterile Water for Injection for a 2 mg vial.6 The general steps are in the mixing guide.
500 mcg of CJC-1295 + Ipamorelin from a 10 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
The worked example is 500 mcg from a 10 mg vial mixed with 2 mL, which is 5 mg per mL, so 500 mcg is 0.1 mL, or 10 units on a U-100 syringe, and 200 mcg is 0.04 mL, or 4 units. Of the people logging a draw, 13% set up 500 mcg at 10 units.10
Doses and schedules reported
The human trials found tested CJC-1295 with DAC under the skin and ipamorelin by intravenous infusion, and an endocrinology review says no controlled clinical studies have directly evaluated CJC-1295 without DAC in humans, so none matches the no-DAC blend sold in the vial.743
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Teichman 2006, CJC-1295 DAC7 | One of four ascending single doses, or two or three weekly or biweekly doses under the skin, against placebo; the authors found it relatively well tolerated, particularly at 30 or 60 microg/kg | Healthy adults aged 21 to 61; no number is given | 28 and 49 days |
| Ionescu 2006, CJC-1295 DAC8 | One injection of 60 or 90 microg/kg | Healthy men aged 20 to 40; no number is given | Sampled before and 1 week after |
| Beck 2014, ipamorelin4 | 0.03-mg/kg intravenous infusions twice daily, against placebo | One hundred seventeen bowel resection patients enrolled, 114 analysed | Postoperative day 1 to 7 or discharge |
An endocrinology review lists forum-reported doses and states they are not evidence-based: 100 to 200 mcg of CJC-1295 without DAC per injection under the skin 1 to 2 times daily, and 200 to 300 mcg of ipamorelin under the skin 2 or 3 injections a day (see how much ipamorelin per day).3 Of the people logging the blend, 19% set up 200 mcg, 16% 500 mcg, 14% 300 mcg and 10% 250 mcg.10 Doses were logged in mcg by 77%, in mg by 15% and in IU by 7%, while the vendor page gives the blend's contents in mg, not IU (growth hormone's own IU are in the HGH IU guide).105
Approval status
An endocrinology review says neither CJC-1295 variant is approved as a therapeutic agent by major regulatory authorities (e.g., FDA, EMA), and that two variants, with and without DAC, circulate commercially in the off-label market.3 The FDA lists CJC-1295 among bulk drug substances that may present significant safety risks in compounding and says available clinical data are limited.9 The same FDA page lists ipamorelin acetate in category 2 and says a published study identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.9
Storage
No regulator, pharmacopoeia or trial stability data for either peptide, mixed or unmixed, appears in the sources searched. The tesamorelin label, a different compound, stores unmixed 2 mg vials at 20°C to 25°C in the original box, protected from light, and says not to store a mixed vial.6
Frequently asked questions
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- US NLM DailyMed and ClinicalTrials.gov (search records written by the researcher from the returned JSON). DailyMed label search for CJC-1295. 2026. dailymed.nlm.nih.gov
- US NLM DailyMed and ClinicalTrials.gov (search records written by the researcher from the returned JSON). DailyMed label search for ipamorelin. 2026. dailymed.nlm.nih.gov
- Frontiers in Endocrinology. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. 2026. pmc.ncbi.nlm.nih.gov
- Int J Colorectal Dis. Ghrelin mimetic ipamorelin for postoperative ileus in bowel resection patients (abstract). 2014. pubmed.ncbi.nlm.nih.gov
- Core Peptides (vendor). CJC-1295 & Ipamorelin Blend (10mg) product page. 2026. take.app
- Theratechnologies via DailyMed. EGRIFTA SV (tesamorelin) full prescribing information (a different GHRH analogue). 2025. dailymed.nlm.nih.gov
- J Clin Endocrinol Metab. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults (abstract). 2006. pubmed.ncbi.nlm.nih.gov
- J Clin Endocrinol Metab. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295 (abstract). 2006. pubmed.ncbi.nlm.nih.gov
- US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. 2026. fda.gov
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted